High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Top Cited Papers
Open Access
- 26 July 2007
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 357 (4), 340-348
- https://doi.org/10.1056/nejmoa067749
Abstract
Metastatic testicular tumors that have not been successfully treated by means of initial chemotherapy are potentially curable with salvage chemotherapy. We conducted a retrospective review of 184 consecutive patients with metastatic testicular cancer that had progressed after they received cisplatin-containing combination chemotherapy. We gave 173 patients two consecutive courses of high-dose chemotherapy consisting of 700 mg of carboplatin per square meter of body-surface area and 750 mg of etoposide per square meter, each for 3 consecutive days, and each followed by an infusion of autologous peripheral-blood hematopoietic stem cells; the other 11 patients received a single course of this treatment. In 110 patients, cytoreduction with one or two courses of vinblastine plus ifosfamide plus cisplatin preceded the high-dose chemotherapy. Of the 184 patients, 116 had complete remission of disease without relapse during a median follow-up of 48 months (range, 14 to 118). Of the 135 patients who received the treatment as second-line therapy, 94 were disease-free during follow-up; 22 of 49 patients who received treatment as third-line or later therapy were disease-free. Of 40 patients with cancer that was refractory to standard-dose platinum, 18 were disease-free. A total of 98 of 144 patients who had platinum-sensitive disease were disease-free, and 26 of 35 patients with seminoma and 90 of 149 patients with nonseminomatous germ-cell tumors were disease-free. Among the 184 patients, there were three drug-related deaths during therapy. Acute leukemia developed in three additional patients after therapy. Testicular tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell rescue, even when this regimen is used as third-line or later therapy or in patients with platinum-refractory disease.Keywords
This publication has 28 references indexed in Scilit:
- High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular CancerJournal of Clinical Oncology, 2000
- Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell CancerJournal of Clinical Oncology, 2000
- Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor PatientsJournal of Clinical Oncology, 2000
- High-dose chemotherapy in germ cell tumours: a large single centre experienceEuropean Journal of Cancer, 1998
- Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.Journal of Clinical Oncology, 1998
- Testicular Germ-Cell CancerThe New England Journal of Medicine, 1997
- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.Journal of Clinical Oncology, 1997
- Surgical salvage of chemorefractory germ cell tumors.Journal of Clinical Oncology, 1993
- Treatment of testicular cancer: a new and improved model.Journal of Clinical Oncology, 1990
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideThe New England Journal of Medicine, 1987